Investigational Drug Information for Sorivudine
✉ Email this page to a colleague
What is the development status for investigational drug Sorivudine?
Sorivudine is an investigational drug.
There have been 6 clinical trials for Sorivudine.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 1997.
The most common disease conditions in clinical trials are Rectal Neoplasms, HIV Infections, and Herpes Zoster. The leading clinical trial sponsors are Genentech, Inc., M.D. Anderson Cancer Center, and Bristol-Myers Squibb.
Summary for Sorivudine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,604 |
| WIPO Patent Applications | 782 |
| Japanese Patent Applications | 183 |
| Clinical Trial Progress | Phase 3 (1997-02-01) |
| Vendors | 27 |
Recent Clinical Trials for Sorivudine
| Title | Sponsor | Phase |
|---|---|---|
| Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles) | aRigen Pharmaceuticals, Inc. | Phase 2 |
| Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | Genentech, Inc. | Phase 1 |
| Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | M.D. Anderson Cancer Center | Phase 1 |
Clinical Trial Summary for Sorivudine
Top disease conditions for Sorivudine
Top clinical trial sponsors for Sorivudine
US Patents for Sorivudine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
